BPC-157 and TB-500 as paired lab topics

Publication status: Prepared for the BlueNex Labs Research Knowledge Centre. Literature and library notes checked September 24, 2026. Primary papers and the public COA library can change; verify the lot report in hand before an assay.

This combination appears under informal names online. This page does not use them. In laboratory discussions it usually means that a paper, or a project plan, mentions BPC-157 beside a thymosin beta-4 fragment. The two sequences are different molecules. They show up together because both have been used in cell-migration, cytoskeletal, and angiogenesis-marker models. The nickname is not a protocol, not a wellness product, and not a mobility routine. This page keeps the literature habit and the catalogue SKUs in separate columns.

Two ligands, two masses

BPC-157 is the gastric pentadecapeptide GEPPPGKPADDAGLV, about 1419 daltons, covered in What is BPC-157? Structure & research. Published gastrointestinal models are reviewed by Sikiric and colleagues (PMID 21548867). A tendon-fibroblast paper reports culture concentrations and growth-hormone receptor expression (PMC6271067). Those citations belong to the pentadecapeptide. They do not describe thymosin beta-4.

TB-500 is catalogued as a thymosin beta-4 fragment. The actin-binding hexapeptide LKKTET, residues 17–22 of the 43-residue protein, was mapped by Vancompernolle and colleagues (PMID 1464307). For the fragment note, see What is TB-500? Actin-fragment research. Actin polymerization in a biochemical assay is not a BPC-157 result, and a gastric lesion model is not a TB-500 result. Cite the sequence you actually dispensed.

Why papers mention both

Cell-migration and vascular-marker assays are common endpoints in both literatures, so secondary articles place the names in one paragraph. Shared endpoints are not shared structure. A method that "tests two peptides" still needs two identity checks, two purity figures, and a statement of whether the wells contained one sequence, the other, or both. If your design adds them together, the combination is a new condition. It is not established by the fact that a supplier sells both powders.

Gwyer, Wragg, and Wilson reviewed rodent musculoskeletal models of the pentadecapeptide and noted the narrow set of laboratories behind much of that work (PMID 30915550). That review is not a manual for combining the pentadecapeptide with an actin-binding fragment. Do not promote a nickname into a method section.

Catalogue fills are convenience, not evidence of synergy

A documented blend is a manufacturing choice: two solids in one vial so a laboratory that already decided to study both can purchase one container. BPC-157 / TB-500 5 mg/5mg and 10 mg/10mg are different milligram splits. Neither blend is evidence that the sequences potentiate each other. The word on the label is the fill, which the COA must confirm.

The public library has four separate Janoshik reports: the 5 mg/5 mg blend, the 10 mg/10 mg blend, BPC-157 10 mg, and TB-500 10 mg (the TB-500 10 mg certificate). Using the 5 mg/5mg PDF to cover the other SKUs would mis-file the study. What is a peptide COA? states the rule: one batch, one document.

Regulatory frame

Advertisements that present either sequence for human administration are drug claims under Canadian law. Health Canada has warned about unauthorized products that use these names. BlueNex Labs lists the vials as research-use-only materials with Canada-only shipping. See Are research peptides legal in Canada?. The July 2026 U.S. advisory meeting did not approve the pentadecapeptide and did not set Canadian rules; the summary is FDA peptide review 2026, Canada.

Receiving either solid

Both SKUs ship lyophilized, inside Canada, after Interac e-Transfer, on Canada Post Xpresspost from the Burnaby desk with a Port Moody PO Box on the label. Store sealed vials as described in peptide storage for Canadian laboratories. Inspect on receipt. This page does not give a mixing ratio for the two powders. If a blend vial is what the protocol already specifies, buy that SKU and match its own report, rather than combining single-peptide cakes using instructions from a blog.

Pathway context for the group is Cellular & Biological Peptides. Thymosin alpha-1 remains a different peptide: its research note should not be cited as TB-500.

How to describe a paired experiment without inventing a stack

If a protocol already calls for both sequences, write two lines in the materials table, not one nickname. Line one is the pentadecapeptide: sequence or catalogue slug, lot, mass result, purity, and the well concentration your method uses. Line two is the thymosin beta-4 fragment, with its own lot and its own mass. If you used the 5 mg/5mg blend vial, say that, and cite the blend report rather than two single-peptide reports you do not have. The materials table is also where you state whether the peptides were applied together or in separate wells. A reader cannot recover that fact from the URL of this article.

Controls stay boring and specific. An actin-polymerization assay needs the actin and salt conditions, because that is what the 1992 thymosin paper varied. A migration assay needs the cell identity and the coating. A gastrointestinal lesion model, if that is really the system, belongs to the BPC-157 literature and should not be labelled as a TB-500 result because the freezer box was shared. Secondary articles that put both names in one sentence are citation habits. They are not data.

Storage does not collapse the two lots into one record either. Log each vial. Use the Canadian storage note for receipt, moisture, and light. Use the COA reading guide when the PDF has both an HPLC table and a mass, which is the usual case for a documented blend and for the single-peptide BPC-157 lot.

Component identification on a blend report

A blend Certificate of Analysis is a different document from a single-compound file. Component identification means each mass the PDF prints is copied next to the sequence the PDF assigns. If the file prints one purity figure and does not assign that figure to one component, copy the figure once and write that it was not split by sequence. Do not divide it by two. The BPC-157 10 mg area percent does not apply to the blend, and the blend figure does not apply to the TB-500-only vial.

The certificates library has separate rows for the 5 mg/5 mg blend, the 10 mg/10 mg blend, BPC-157 10 mg, and TB-500 10 mg. Each row documents only its own fill. The 5 mg/5 mg PDF does not cover the other three.

One cake, two sequences

A blend vial arrives as one lyophilized solid. The two sequences are not visible as layers, and they should not be separated by eye or by scraping a portion of the cake. Residual water can affect every chain in that cake. This page does not list a diluent volume. The fill is a catalogue format: two named constituents in one glass so a laboratory that already decided to hold both sequences can purchase one container. It is not a combined method, and it is not a use instruction. If the study needs only one sequence, buy the single-peptide SKU and match that SKU's own report.

Frequently asked questions

Is the BPC-157 and TB-500 note a protocol?

No. It is a literature note about two different sequences that appear in overlapping cell-migration papers. It is not a combined method, a nickname product, or an instruction for people or animals.

Does one Certificate of Analysis cover both single-peptide vials and the blend?

No. The BPC-157 10 mg lot has its own library anchor. The 5 mg/5mg blend has a separate Janoshik report. The TB-500-only vial and the 10 mg/10 mg blend each have their own report. Do not copy one PDF across SKUs.

What does research use only mean for these two sequences?

Each solid is supplied for laboratory work. Pairing the names on this page does not create a Health Canada authorization for either sequence or for the blend.

How are the blend vials fulfilled in Canada?

The 5 mg/5mg and 10 mg/10mg fills ship inside Canada after Interac e-Transfer checkout, on Canada Post Xpresspost, from the Burnaby operation. Store the sealed vials promptly after the parcel arrives.

How is purity recorded when a blend report shows one figure?

Copy the printed figure. If the PDF does not assign that figure to one component, do not split it across BPC-157 and TB-500. Each mass stays with the sequence the report names.

Catalogue cross-reference

If a lab wants both sequences in one vial, the convenience SKUs are 5 mg/5mg and 10 mg/10mg. The nickname on this URL is historical search residue, not a protocol name.

Orders ship inside Canada only after Interac e-Transfer checkout. Sold-out SKUs remain listed and cannot be added to the cart. Match each vial to its own Certificate of Analysis when a lot is published. Research use only. Not for human or veterinary use.